Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could differentiate ...
NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing ...
Beam Therapeutics announced positive updates on its BEAM-101 treatment for sickle cell disease (SCD) from the BEACON Phase 1/2 clinical trial, with results presented at the European Hematology ...
CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...
Eilersen has announced it is releasing a new series of digital load cells in a hygienic (aseptic) design. The new product is targeted at food and pharmaceutical industry customers and is used for ...
Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc. (NASDAQ:BEAM) announced new efficacy and safety findings from its BEACON Phase 1/2 ...
CAMBRIDGE - Beam Therapeutics Inc. (NASDAQ:BEAM) released updated clinical data from 31 patients treated with its experimental sickle cell disease (SCD) gene therapy, showing sustained benefits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results